BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38345246)

  • 1. A Clinicopathological Appraisal of Duodenal Neuroendocrine Tumors at a Racially Diverse Safety Net Hospital.
    Shaikh SD; Jacoba I; Sun N; Chung E; Kim HT; Zhao Q; Weber HC
    Am J Gastroenterol; 2024 Mar; ():. PubMed ID: 38345246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Duodenal Neuroendocrine Tumors: Surgical versus Endoscopic Mucosal Resection.
    Tran CG; Sherman SK; Suraju MO; Nayyar A; Gerke H; Abiad RGE; Chandrasekharan C; Ear PH; O'Dorisio TM; Dillon JS; Bellizzi AM; Howe JR
    Ann Surg Oncol; 2022 Jan; 29(1):75-84. PubMed ID: 34515889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgical outcomes of patients with duodenal vs pancreatic neuroendocrine tumors following pancreatoduodenectomy.
    Dong DH; Zhang XF; Lopez-Aguiar AG; Poultsides G; Rocha F; Weber S; Fields R; Idrees K; Cho C; Spolverato G; Maithel SK; Pawlik TM
    J Surg Oncol; 2020 Sep; 122(3):442-449. PubMed ID: 32470159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for lymph node metastasis and indication of local resection in duodenal neuroendocrine tumors.
    Nakao E; Namikawa K; Hirasawa T; Nakano K; Tokai Y; Yoshimizu S; Horiuchi Y; Ishiyama A; Yoshio T; Nunobe S; Fujisaki J
    JGH Open; 2022 Mar; 6(3):189-195. PubMed ID: 35355673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endoscopic Management of Diminutive Duodenal Neuroendocrine Tumors.
    Klemm N; Lu-Cleary D; Chahal D; Trasolini R; Lam E; Donnellan F
    J Gastrointest Cancer; 2021 Jun; 52(2):448-453. PubMed ID: 33471257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparable long-term survival outcomes of endoscopic therapy versus surgical therapy for T1-2N0M0 duodenal neuroendocrine tumors.
    Liu Z; Gao J; Wang P; Yin F; Zeng C; Chen Y
    Surg Endosc; 2023 Jul; 37(7):5444-5452. PubMed ID: 37036503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of clinicopathological characteristics, therapeutic strategy and prognosis of 501 patients with gastric neuroendocrine neoplasms attending a single center].
    Zhang BL; Lu YX; Liang WQ; Gao YH; Xi HQ; Wang XX; Zhang KC; Chen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):459-466. PubMed ID: 37217354
    [No Abstract]   [Full Text] [Related]  

  • 8. Impact of margin status on outcomes after endoscopic resection of well-differentiated duodenal neuroendocrine tumors.
    Ragheb J; Mony S; Klapman J; Erim T; Reagan A; Butler R; Dong Y; Cruise M; Centeno BA; Bejarano P; Stevens T; Hayat U; Bhatt A
    Gastrointest Endosc; 2021 Sep; 94(3):580-588. PubMed ID: 33676923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ASO Author Reflections: Endoscopic Management is Reasonable for <2 cm Duodenal Neuroendocrine Tumors.
    Tran CG; Sherman SK; Howe JR
    Ann Surg Oncol; 2022 Jan; 29(1):85-86. PubMed ID: 34608558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endoscopic resection using an over-the-scope clip for duodenal neuroendocrine tumors.
    Tashima T; Ryozawa S; Tanisaka Y; Fujita A; Miyaguchi K; Ogawa T; Mizuide M; Mashimo Y; Kawasaki T; Yasuda M
    Endosc Int Open; 2021 May; 9(5):E659-E666. PubMed ID: 33937505
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparisons of therapeutic outcomes in patients with nonampullary duodenal neuroendocrine tumors (NADNETs): A multicenter retrospective study.
    Lee SW; Sung JK; Cho YS; Bang KB; Kang SH; Kim KB; Kim SH; Moon HS; Song KH; Kim SM; Chung IK; Lee DS; Jeong HY; Youn SJ
    Medicine (Baltimore); 2019 Jun; 98(26):e16154. PubMed ID: 31261543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinicopathologic features and prognostic analysis of 240 patients with gastric neuroendocrine neoplasms].
    Liang WQ; Zhang W; Qiao S; Wang BH; Wang C; Zhuang ZW; Xi HQ; Cai AZ; Wei B; Chen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Jan; 23(1):38-43. PubMed ID: 31958929
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinicopathological features and multivariate analysis of prognostic factors for patients with gastroenteropancreatic neuroendocrine tumors].
    Wang X; Song ZF; Yao WX; Pan CC; Xiang MF; Wang H
    Zhonghua Yi Xue Za Zhi; 2013 May; 93(18):1411-4. PubMed ID: 24025507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
    Tang LH; Basturk O; Sue JJ; Klimstra DS
    Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duodenal neuroendocrine tumors: Impact of tumor size and total number of lymph nodes examined.
    Zhang XF; Wu XN; Tsilimigras DI; Poultsides G; Rocha F; Abbott DE; Fields R; Idrees K; Cho C; Maithel SK; Pawlik TM;
    J Surg Oncol; 2019 Dec; 120(8):1302-1310. PubMed ID: 31680243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endoscopic mucosal resection using a ligation device for duodenal neuroendocrine tumors: a simple method.
    Inokuchi Y; Hayashi K; Kaneta Y; Okubo Y; Watanabe M; Furuta M; Machida N; Maeda S
    Ther Adv Gastrointest Endosc; 2022; 15():26317745221103735. PubMed ID: 35706683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognoses in patients with primary gastrointestinal neuroendocrine neoplasms based on the proposed new classification scheme.
    Yin XN; Shen CY; Yin YQ; Chen HJ; Chen HN; Yin Y; Han LY; Chen JJ; Tang SM; Chen ZX; Zhang B
    Asia Pac J Clin Oncol; 2018 Apr; 14(2):e37-e44. PubMed ID: 28856815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Digestive neuroendocrine tumors (DNET): the era of targeted therapies.
    Boussaha T; Rougier P; Taieb J; Lepere C
    Clin Res Hepatol Gastroenterol; 2013 Apr; 37(2):134-41. PubMed ID: 23562338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of endoscopic resection techniques for duodenal neuroendocrine tumors: systematic review.
    Brito HP; Torres IT; Turke KC; Parada AA; Waisberg J; Botelho RV
    Endosc Int Open; 2021 Aug; 9(8):E1214-E1221. PubMed ID: 34447867
    [No Abstract]   [Full Text] [Related]  

  • 20. Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target.
    Karhoff D; Sauer S; Schrader J; Arnold R; Fendrich V; Bartsch DK; Hörsch D
    Neuroendocrinology; 2007; 85(1):45-53. PubMed ID: 17341847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.